Education
About Us
Working with TipRanks
Follow Us
Nanovibronix (NAOV)
:NAOV
NAOV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.67 - $16.25
Previous CloseN/A
Volume412.44K
Average Volume (3M)5.90M
Market Cap
$2.61M
Enterprise Value$5.77M
Total Cash (Recent Filing)$601.00K
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta3.52
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.72
Shares Outstanding2,584,835
10 Day Avg. Volume1,651,403
30 Day Avg. Volume5,899,174
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.75
Enterprise Value/Market Cap2.21
Enterprise Value/Revenue0.49
Enterprise Value/Gross Profit4.76
Enterprise Value/Ebitda-0.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoVibronix News
PremiumCompany Announcements
NanoVibronix Secures $8 Million Through Securities Agreement
PremiumCompany Announcements
NanoVibronix Approves Reverse Stock Split Proposal
PremiumCompany Announcements
NanoVibronix Adjourns Special Meeting Due to Quorum
PremiumMarket News
3 Penny Stocks to Watch Now, 6/12/25
PremiumCompany Announcements
NanoVibronix Appoints Doron Besser as New CEO
Options Prices
Currently, No data available
---
Ownership Overview
5.07%
Insiders
0.11% Mutual Funds
26.34% Other Institutional Investors
94.72% Public Companies and Individual Investors
NAOV FAQ
What was Nanovibronix’s price range in the past 12 months?
Nanovibronix lowest stock price was $0.67 and its highest was $16.25 in the past 12 months.
What is Nanovibronix’s market cap?
Nanovibronix’s market cap is $2.61M.
When is Nanovibronix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nanovibronix’s earnings last quarter?
Currently, no data Available
Is Nanovibronix overvalued?
According to Wall Street analysts Nanovibronix’s price is currently Overvalued.
Does Nanovibronix pay dividends?
Nanovibronix does not currently pay dividends.
What is Nanovibronix’s EPS estimate?
Nanovibronix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nanovibronix have?
Nanovibronix has 2,584,835 shares outstanding.
What happened to Nanovibronix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanovibronix?
Currently, no hedge funds are holding shares in NAOV
Company Description
Nanovibronix
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.